Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm TaiwanTPE:1789 +2.64%77 Cyclically Adjusted PS Ratio is 4.00 as of Aug. 20, 2026, which is 15% below its 10-year median of 4.73. GuruFocus rates TPE:1789 with a GF Score™ of 77/100 and a GF Value™ of NT$20.21 (Fairly Valued). The stock has 8 warning signs investors should review. Among 750 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 69.6% on this metric.
The historical rank and industry rank for Scinopharm Taiwan's Cyclically Adjusted PS Ratio or its related term are showing as below:
TPE:1789'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.33 Med: 4.73 Max: 7.18
Current: 3.9
During the past years, Scinopharm Taiwan's highest Cyclically Adjusted PS Ratio was 7.18. The lowest was 3.33. And the median was 4.73.
TPE:1789's Cyclically Adjusted PS Ratio is ranked worse than 69.6% of 750
companies
in the Drug Manufacturers industry
Industry Median: 2.045
vs TPE:1789: 3.90
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Scinopharm Taiwan's adjusted revenue per share data for the three months ended in Jun. 2026 was NT$0.764. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$4.86 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Scinopharm Taiwan (TPE:1789) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Scinopharm Taiwan Cyclically Adjusted PS Ratio Related Terms
Scinopharm Taiwan Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan Cyclically Adjusted PS Ratio Chart
TPE:1789 vs ZTS: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Cyclically Adjusted PS Ratio falls into.
Scinopharm Taiwan Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Scinopharm Taiwan's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 4.00 mean?
Scinopharm Taiwan (TPE:1789) has a Cyclically Adjusted PS Ratio of 4.00 as of Aug. 20, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors. This is 15% below median its historical median of 4.73. Over the past decade, Scinopharm Taiwan's Cyclically Adjusted PS Ratio has ranged from 3.33 to 7.18. According to the industry distribution chart, Scinopharm Taiwan ranks #522 out of 750 companies in the Drug Manufacturers industry, placing it in the top 69.6%.
Is Scinopharm Taiwan's Cyclically Adjusted PS Ratio too high?
Scinopharm Taiwan's current Cyclically Adjusted PS Ratio of 4.00 is 15% below median its 10-year median of 4.73. Over the past 10 years, this metric has ranged from a low of 3.33 to a high of 7.18. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 2.05. Scinopharm Taiwan's value of 4.00 is 95.6% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #522 out of 750 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Cyclically Adjusted PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #522 out of 750 companies for Cyclically Adjusted PS Ratio. This places Scinopharm Taiwan in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.05. Scinopharm Taiwan's value of 4.00 is 95.6% above this benchmark. Historically, Scinopharm Taiwan's own Cyclically Adjusted PS Ratio has ranged from 3.33 to 7.18 over the past decade. While the company's 10-year median is 4.73 vs. the industry median of 2.05, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 2.05, based on 750 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current Cyclically Adjusted PS Ratio of 4.00 is 95.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Cyclically Adjusted PS Ratio is 4.00, which is 15% below median its own 10-year median of 4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.21, compared to a current price of NT$19.45 — trading 3.8% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 4.00, which is 15% below median its 10-year median of 4.73 and 95.6% above the Drug Manufacturers industry median of 2.05. Scinopharm Taiwan's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Cyclically Adjusted PS Ratio is 4.00 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.45 is trading 3.8% below its estimated GF Value™ of NT$20.21.
GuruFocus considers Scinopharm Taiwan to be Fairly Valued.
Key valuation signals for TPE:1789:
Cyclically Adjusted PS Ratio: 4.00 (15% below median its 10-year median of 4.73)
GF Value™: NT$20.21 vs. price of NT$19.45 (3.8% below fair value)
Industry Position: 95.6% above the Drug Manufacturers median (#522 of 750)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
77GF Score
Get the complete analysis for TPE:1789
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
